Life science fam, is your FP&A stuck in the Stone Age (aka Microsoft Excel)? Exigyn blasts off soon! ✅industry-specific, ✅sleek dashboards, ✅turnkey budgeting ✅clinical trial model ❌consultant chaos = BYE. ❌implementation fees Trailer incoming, be the first ten to signup & win prizes! #biotech #lifesciences #saas #innovation #teaser #comingsoon #excited #gamechanger https://exigyn.com/ 🔥
Exigyn
Software Development
San Francisco, CA 1,295 followers
We're in business to help Life Science companies budget & plan smarter.
About us
Our software is expertly crafted to empower Life Science companies in their most critical mission – expediting the development of innovative therapies and technologies poised to revolutionize healthcare. Designed with precision, it streamlines and enhances the Budgeting & Planning processes, equipping businesses with real-time insights for more intelligent decision-making and robust risk management. By simplifying complex financial tasks, our solution enables these companies to concentrate their efforts on breakthroughs that matter, ensuring that every step taken is a stride towards transformative healthcare advancements.
- Website
-
www.exigyn.com
External link for Exigyn
- Industry
- Software Development
- Company size
- 2-10 employees
- Headquarters
- San Francisco, CA
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Biotech, Pharma, Life Sciences, FP&A, Clinical Trials, Budgeting, and Forecasting
Products
![Click here to view Exigyn]()
Exigyn
Budgeting Software
Exigyn stands out as a pioneering budgeting and planning software crafted for the life science industry, marking a departure from traditional, often cumbersome financial tools. Developed by experts with extensive biotech/pharma background, it aims to simplify financial planning with its bioBudget feature, a ready-to-use, implementation-free budget model tailored for the fast-paced needs of life sciences, enabling swift, efficient planning without the usual setup complexities.
Locations
-
Primary
Get directions
San Francisco, CA 94118, US
Employees at Exigyn
Updates
-
**💡 Trying to keep your cash burn low while staying focused on key milestones? 👇🏻 Over 90% of life sciences companies still rely on Excel for managing finances, but that can mean missed insights and time-consuming updates—especially when trying to control cash burn and reach critical valuation milestones. At Exigyn, we’ve built a "Carta-style" prebuilt model that delivers real-time visibility into your cash runway and key metrics. It’s all about staying lean and focused, without getting bogged down by manual spreadsheets. We’re here to help streamline your process and keep you on track toward those major milestones. 📊💡 #lifesciences #biotech #financialplanning #budgeting #startups #exigyn #biotechstartups #pharma #CFO #cashrunway #valuation #capitalstrategy #biopharma #healthcarefinance #clinicaltrials #earlystagebiotech #biotechnology #sciencestartups #pharmaceuticals #drugdevelopment #excelalternatives #financialmodels #strategicplanning #biotechstrategy #pharmastartups #lifehealthcare #venturecapital #biotechfunding #cashmanagement #finance #growthstrategy
I have started, built, and exited several biotech companies (over $6B in exit value). Unusually, my companies are started as university spin-outs. I bootstrapped each of them using creative financing techniques and only taking institutional money once the valuation was high enough to ensure control by the founder group through exit. In starting up the companies, there was a general formula I applied (used by many of us serial entrepreneurs). 1. Obtain the in vivo technical proof of concept as cheaply and as quickly as possible. If the technology is going to fail, you want it to do so quickly. 2. Scale up the technology. Lots of technologies that look great in the lab can’t be scaled for commercial production. Scale-up should be done before commencement of clinical trials (else you may have to do them over). With biologics, the process is the product. 3. Determine the regulatory path. If a platform technology, pick a first indication where the FDA hurdles will be lower (like devastating rare disease with unmet need). 4. Hire the start-up team. This is a scrappy bunch that can do multiple functions and is used to a start up environment. This team will likely be replaced as the company grows and becomes more systematized. 5. Determine the manufacturing plan. Out-source if good, affordable alternatives exist. 6. Compile the budget and financing plan. Keep cash burn as low as possible (use options where possible). Determine the valuation inflection points and the amount of cash to get to each. This sets your financing strategy. I’ve never wanted to go public so I usually determine what’s necessary to exit after human POC is achieved. 7. Raise money initially from friends and family and non-dilutive means, followed by institutional investors. Find investors who want to be helpful in building the business and can provide value through connections and advice. Chemistry is key. An investor-founder relationship is like a marriage. It can be great or very harmful. 8. Find items to monetize. Are there services, data, or IP that can be sold or licensed? 9. Pursue collaborations to share risk and benefit from others expertise or technology. 10. Get a strong IP position. Think outside of patents to biologics market exclusivity and rare disease exclusivity. #biotech #startup #entrepreneurship
-
-
🤔 What do all the FP&A tools on the market have in common? 👇 They're industry-agnostic. But at Exigyn, we believe that one size does not fit all. That's why we've built an AI-powered platform specifically for the Life Sciences sector, bringing precision, insight, and agility to your financial operations. 💡🔬 www.exigyn.com Ready to upgrade to a tool that truly understands your business? 🚀 Credit to The FP&A Guy for the guide cited. #Biotech #LifeSciences #AIinBiotech #BiotechInnovation #PharmaTech #BiotechStartup #HealthcareInnovation #BiotechInvesting #BiotechFunding #ClinicalTrials #DrugDevelopment #Pharmaceuticals #Biotechnology #MedTech #LifeSciencesStrategy #PrecisionMedicine #HealthcareAI #R&D #DigitalHealth #HealthcareIT #MedicalResearch #BiotechGrowth #HealthcareStartups #PharmaR&D #BiotechFunding #BiotechResearch #AIinHealthcare #HealthTech #VentureCapital #PharmaInnovation #Exigyn #AIRevolution Business Partnering Institute
-
Let's get ready for an exciting IPO market comeback! 🚀💼 #IPOMarket #EquityCapital #MarketTrends #IPOReadiness #InvestmentBanking #FinancialGrowth
-
Why settle for generic FP&A tools when Exigyn offers the future of financial planning and analysis for Life Sciences? 🌟 www.exigyn.com #LifeSciences #FPandA #FinancialPlanning #Biotech #AI #GPTAI #TurnkeySolution #Implementation #HealthcareAI #DataAnalytics #BioTechIndustry #PrecisionMedicine #Pharmaceuticals #Biotechnology #ClinicalTrials #HealthcareInnovation #MedTech #Bioinformatics #HealthTech #Budgeting #Finance #SaaS #FinancialServices #ArtificialIntelligence #TechInnovation #LifeScienceAI #DigitalHealth #HealthcareFinance #FPandASolutions #BiotechFinance #AIinHealthcare #FinancialInsights
-
-
🎉 Congratulations to the AIRNA Team! 🎉 We are thrilled to see Airna’s impressive achievement in securing an additional $60 million for their Series A round! 🚀 Your groundbreaking work in RNA editing and genetic medicine for complex diseases like lung, cardiovascular, metabolic, and blood disorders is truly inspiring. 🌟 With this new funding, Airna is set to advance its AATD drug candidate into the clinic next year—a significant step forward in the fight against rare genetic disorders. 🙌 Your innovative approach, using RNA as the "software" of the cell to complement traditional DNA editing techniques, is paving the way for safer and more effective treatments. 💡 A big shoutout to the leadership and team for your dedication and visionary science that holds the promise of transformative impacts on patient care. 👏👏 Here’s to continued success and groundbreaking discoveries! 🌟 #Biotech #GeneticMedicine #RNAEditing #HealthcareInnovation #SeriesAFunding #Airna #MedicalResearch #LungDisease #CardiovascularDisease #MetabolicDisorders #BloodDiseases #AATD #CRISPRAlternatives #DNAEditing #RNAScience #DrugDevelopment #HealthTech #Biotechnology #Startups #Investments #LifeSciences #ClinicalTrials #GeneticTherapy #MedicalBreakthroughs #BiotechNews #FundingSuccess #ResearchAndDevelopment #PharmaNews #HealthInnovation #ScientificResearch #BiotechStartups #Genomics #MedicalTechnology #FutureOfMedicine
Public and Private Company Biotech CFO, Founder of Collabrity and the Collabrity Report
August 01 and July 31, 2024 headlines from the Collabrity Report, a daily summary of financings for therapeutic biotechnology company executives and investors - www.collabrityreport.com New! Collabrity Report (CR) Analytics Otsuka’s $800 Million Acquisition of Jnana MilliporeSigma’s $600 Million Acquisition of Mirus venBio’s $528 Million Fund Raise Outpace’s $144 Million Series B Jade’s $80 Million Venture Financing Airna’s $60 Million Series A Healx’s $47 Million Series C Ocugen’s $35 Million Public Offering SELLAS’s $21 Million Registered Direct IMUNON’s $10 Million Registered Direct OS Therapies’s $6 Million Public Offering
-
At Exigyn, we've found that AI's real-time value varies significantly based on the specific use cases and the readiness of the organization to integrate these tools. It's not just about having the technology, but about aligning it with well-defined business goals and providing adequate training. While the future potential is immense, the immediate ROI must be clear and measurable. This is why we emphasize targeted deployment for Finance Professionals in 💉 Life Sciences and continuous evaluation to ensure that AI investments yield tangible benefits today and pave the way for tomorrow's advancements. #AI #GenerativeAI #Workflows #BusinessGoals #Training #FuturePotential #ROI #TechIntegration #ImmediateValue #OrganizationalReadiness #TargetedDeployment #ContinuousEvaluation #TangibleBenefits #FutureAdvancements #TechInvestment #RealTimeValue #BusinessImpact #Innovation #Efficiency #AITraining #TechAdoption #StrategicPlanning #AIImplementation #ValueCreation #DigitalTransformation #BusinessStrategy #TechROI #DataDriven #AIInBusiness #Exigyns #AIInsights
“A pharma company stopped using Microsoft's Copilot AI tool, with an exec citing high cost and low value.” “He compared the slide-generation capability of Microsoft's AI tools to middle school presentations, according to a transcript of a call with the Morgan Stanley analysts that was included in their research note.” “The chief information officer of a pharma company paid extra to have 500 employees use Office 365 Copilot in the fourth quarter of 2023 and first quarter of 2024. This is Microsoft's much-heralded AI upgrade to its popular suite of productivity software.” He paid “about $34 per user a month” for the “E3 version of Microsoft's 365 software suite.” “Adding Copilot AI features costs another $30 per user a month. For 500 employees, that would roughly add an extra $180,000 a year.” “These new Microsoft tools are considered some of the premier examples of powerful artificial intelligence in action in the real world. Investors have bid up Microsoft and other big #tech shares massively, betting that this product and similar offerings will catch on with paying customers.” But the article says: “If a large pharma company can't see $180,000 of value in these tools, that's a problem that should worry the entire tech industry,” a worry that I have written about many times. I have trouble finding any examples of companies claiming productivity improvements from generative text AI, and only a few for generative video AI (marketing videos and helping with movie and TV shows). There was one AI feature that the IT executive found somewhat compelling: that “was the ability to archive and summarize video meetings on Microsoft's Teams app. But he said his legal team was wary of retaining meeting transcripts, so the pharma company didn't use that feature.” Other people have shared their concerns with me about the legal problems from storing their proprietary information like this. Investors are also concerned and thus there are many comments, both internal and external to Microsoft, about “whether its AI services will create enough value to persuade corporate customers to pay more.” “The company is amassing 1.8 million graphics processing units to build and run AI models and related products. It also has a plan to triple data-center capacity, mainly to handle AI workloads. Its capital expenditure hit a record $14 billion in the most recent quarter.” Many investors are concerned that this pharma company isn’t the only company that is finding Microsoft’s Copilot AI services, and those from other companies, not as beneficial as many proclaim. With a big runup in the market capitalizations of the big tech companies over the last 18 months, particularly of the so-called Magnificent 7, those concerns could spark a move in the opposite direction for the share prices of the Magnificent 7. #technology #innovation #startups #ethics #artificialintelligence https://lnkd.in/gJ_FHBAB
-
-
Biotech IPO Surge in Q1 2024: A Temporary Boost or Lasting Momentum? 👇 📈 According to GlobalData, the biotech IPO value raised in Q1 2024 surpassed any quarter of 2023! This surge comes after a notable decline in completed IPOs, which fell from $30.8 billion in 2020 to $5.9 billion in 2022, and further down to $4.4 billion in 2023. High interest rates during 2022 and 2023 contributed to this decline, as investors prioritized existing portfolios over new opportunities, prompting many companies to delay their IPOs until market conditions improved. 💡 Notable IPOs and Market Impact 🧬 The first and largest biotech IPO of Q1 2024 was by clinical-stage CG Oncology, which raised $437 million for its pioneering oncolytic virus therapy, CG-0070. Despite a decline in the volume of completed IPOs in Q2 2024, companies with strong clinical data that previously struggled to secure private funding may now view the early successes of 2024 as a green light to pursue their own public offerings. 💰 In the first half of 2024, six completed IPOs each raised over $100 million, collectively amassing nearly $5 billion. This figure is more than double the high-value offerings seen in the first half of 2023, which had five completed IPOs worth $2.2 billion. These high-value IPOs, coupled with increased venture funding, have sparked renewed optimism among investors. 🌍 Global and Regional Highlights 🌎 In 2024, biotech companies in Switzerland, the US, and India reported the highest total IPO raises, with $2.5 billion, $1.5 billion, and $273 million respectively. Meanwhile, the recent regulatory shake-up by Britain’s Financial Conduct Authority aims to loosen listing requirements on the London Stock Exchange. This initiative seeks to revitalize Britain’s capital markets and enhance London’s global competitiveness post-Brexit, potentially positioning it as a rival to financial hubs like New York and the EU. 🔮 A Positive Shift and Future Prospects 🌟 The completion of biotech IPO raises in the first half of 2024 marks a positive shift after a prolonged downturn. This resurgence not only reflects renewed investor optimism but also creates new opportunities for companies with strong clinical data. While the success of biotech firms that went public in early 2024 may encourage more companies to follow suit in the latter half of the year, investors remain cautious as market conditions continue to stabilize. #Biotech #IPO #Investment #Q12024 #Growth #Pharma #Healthcare #Biotechnology #GlobalData #MarketTrends #ClinicalData #VentureCapital #InvestorOptimism #Funding #FinancialMarkets #StockExchange #RegulatoryChanges #LondonStockExchange #FinancialHub #Innovation #FutureProspects #BiotechBoom #MarketAnalysis #EconomicTrends #BusinessGrowth #HealthcareInnovation #Oncology #ViralTherapies #BiotechNews #InvestmentTrends #FinancialGrowth
-
-
How Could a Potential Harris Presidency Could Make a Difference? 👇 As VP Kamala Harris enters the presidential race, her strong stances on reproductive rights and drug access offer valuable insights into her potential future actions. From advocating for abortion rights to increasing access to affordable medications, Harris's vision for US healthcare is taking shape. With President Joe Biden's endorsement and over 500 others, Harris's campaign is gaining momentum. But what does this mean for the future of US healthcare? Key Focus of the Harris Administration: Protect and expand reproductive rights Lower drug costs through Medicare negotiations Combat the opioid crisis with increased access to Narcan and substance abuse treatment #USHealthcare #KamalaHarris #ReproductiveRights #AffordableMedications #OpioidCrisis #HealthcarePolicy #PresidentialRace #HealthcareReform #PharmaceuticalIndustry #Medicare #Narcan #SubstanceAbuseTreatment #HealthcareAccess #HealthcareEquity #HealthcareLeadership #HealthcareInnovation #HealthcarePolicyReform #HealthcareNews #HealthcareUpdate #HealthcareAwareness #HealthcareMatters #HealthcareForAll #HealthcareEquality #HealthcareIsAHumanRight
-
-
Revolutionize your Financial Planning & Analysis (FP&A) with Exigyn's OptimAI! Try it today: https://lnkd.in/gypBQP9f #Exigyn #OptimAI #FP&A #FinancialPlanning #LifeSciences #Pharmaceuticals #Biotechnology #MedicalDevices #Healthcare #FinancialAnalysis #MachineLearning #ArtificialIntelligence #PredictiveModeling #ScenarioPlanning #RiskManagement #HeadcountPlanning #TalentManagement #DepartmentalSpend #ModelManagement #FinancialReporting #Compliance #FinancialGovernance #FinancialPlanningAndAnalysis #LifeScienceFinance #FinancialInnovation #DigitalTransformation #FinancialTechnology #FinTech #LifeScienceTech #FinancialSolutions #FinancialTools #FinancialSoftware #FinancialApplications" #biotech #clinicalaccruals #auxilius #condorsoftware #condor #clinicalforecasting #clinicalbudgeting #cubeFPnA #cubesoftware #anaplan #netsuite #oracle #adaptiveplanning #workday #RnDlogic